BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

“ZPC-21’s preclinical activity across multiple models suggest best-in-class potential against ROR1, a clinically validated target that is relevant to both solid tumors and hematological ...

In particular, ROR1 is an RTK known to be involved in multiple human cancers. Now, researchers in Japan have confirmed that a subpopulation of partial EMT-like cells expressing ROR1 can promote ...

It builds on our extensive clinical experience with zilovertamab, as well as that with zilovertamab vedotin, an antibody drug conjugate, which has shown that ROR1 can be targeted without unwanted ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC ...